Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

73 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess whether adding cognitive behavioral therapy to the antidepressant escitalopram is effective in reducing anxiety in older adults with generalized anxiety disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

NCT00219349

Generalized Anxiety Disorder

COMPLETED PHASE4

Treatment of Hypochondriasis With CBT and/or SSRI

NCT00339079

Hypochondriasis

COMPLETED PHASE1/PHASE2

Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder

NCT00074802

Social Anxiety Disorder

COMPLETED PHASE3

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

NCT06004115

Depression, Anxiety Fear Depression +3 more

RECRUITING PHASE4

A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder

NCT00635999

Generalized Anxiety Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Generalized anxiety disorder (GAD) affects nearly 6.8 million adults in the United States. GAD is diagnosed when a person spends at least 6 months excessively worrying over everyday problems to the point that carrying out normal life becomes difficult. People with GAD face each day with intense anxiety and tension and are unable to alleviate their worries. Physical symptoms of GAD include muscle aches, nausea, sweating, exhaustion, irritability, frequent urination, shaking, and hot flashes. People with GAD often experience other anxiety disorders, depression, or substance abuse, all of which can worsen symptoms of GAD. This makes early and appropriate treatment for GAD important. Current treatments for GAD include medication and/or types of psychotherapy. This study will assess whether adding cognitive behavioral therapy (CBT) to the antidepressant escitalopram is effective in reducing anxiety in older adults with GAD.

Participation in this double-blind study will last up to 13 months. Participants will be asked to stop any current treatments for anxiety or depression for the duration of the study. Participants will begin taking one pill of the medication escitalopram daily for 12 weeks. Dosage will be increased to two pills each day if symptoms do not improve within 4 weeks. After 12 weeks, all participants will continue taking escitalopram for an additional 16 weeks. In addition, some participants will be randomly assigned to receive 16 weekly sessions of CBT, lasting 1 hour each. CBT sessions will involve learning relaxation techniques and other skills to manage anxiety and completing 30-minute at-home practice assignments each day. A family member will accompany participants to the first four CBT sessions. All participants will be asked to provide information for a close contact, who will be interviewed at baseline, Month 3, and Month 7 about how the participant's anxiety is affecting his or her relationships.

After the 16-week period, participants will again be randomly assigned to receive either continued escitalopram or a placebo for an additional 28 weeks. Participants assigned to the placebo will be gradually tapered off escitalopram over a 6-week period. Participants who were receiving CBT will receive three more sessions. Throughout the study, participants will be asked to complete various assessments, including questionnaires, memory and thinking tests, and attention evaluations. Blood samples will be taken at Weeks 2 and 8, and saliva samples will be taken at baseline and Weeks 12, 28, and 56.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Generalized Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CBT/Escitalopram

12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

20 mg daily oral escitalopram

Cognitive behavioral therapy (CBT)

Intervention Type BEHAVIORAL

16 weekly 1-hour sessions

No CBT/escitalopram

12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.

Group Type ACTIVE_COMPARATOR

Escitalopram

Intervention Type DRUG

20 mg daily oral escitalopram

CBT/placebo

12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo pill of daily oral escitalopram

Cognitive behavioral therapy (CBT)

Intervention Type BEHAVIORAL

16 weekly 1-hour sessions

No CBT/placebo

12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo

12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo pill of daily oral escitalopram

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

20 mg daily oral escitalopram

Intervention Type DRUG

Placebo

Placebo pill of daily oral escitalopram

Intervention Type DRUG

Cognitive behavioral therapy (CBT)

16 weekly 1-hour sessions

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lexapro Sugar pill CBT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Principal (i.e., most severe or pressing problem) or co-principal current diagnosis of generalized anxiety disorder
* Pretreatment score of at least 17 on Hamilton Anxiety Rating Scale

Exclusion Criteria

* Principal diagnosis other than GAD
* Clinically judged too psychiatrically unstable to participate in the study
* Cognitive impairment or dementia
* Alcohol or other substance use disorder within 6 months prior to study entry
* Lifetime diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder
* Serious, unstable, or terminal medical condition that would compromise study participation or preclude the use of escitalopram, as determined by a review of medical records
* Use of psychotropics that could not be safely tapered and discontinued for at least 2 weeks prior to study entry
* Use of depot neuroleptics within 6 weeks prior to study entry
* Unwillingness to terminate other forms of psychotherapy
* Already received adequate trial of escitalopram or CBT

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No